Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P4RTY
2023-506032-33-00Phase 3Authorised
- Sponsor
- Universitätsmedizin Essen
- Start
- Jul 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of gallium ga-68 gozetotide in prostate cancer (PCa) (2 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Progression-free survival. Planned start Jul 2025; status: authorised.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-506032-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506032-33-00.